(PO07-07-22) Effects of Milk Polar Lipids on Cardiometabolic Disease Risk Factors, Gut Microbiome, and Lipid Metabolites in Healthy Adults

The ePoster content is available to NUTRITION 2022 LIVE ONLINE attendees who are logged in.<br><br>If you are registered, log in and then come back here to use this button.

Presenting Author(s)

LA

Liya Anto, PhD
– Graduate and teaching assistant, University of Connecticut, Storrs, Connecticut, United States

Co-Author(s)

PD

Paige Dossias
– University of Connecticut
EW

Erin Wu
– University of Connecticut
Chelsea M. Garcia, BS
– Graduate Research Assistant, University of Connecticut, VERNON ROCKVILLE, Connecticut, United States
SW

Sarah Wen Warykas
– University of Connecticut
CB

Christopher N. Blesso, PhD
– University of Connecticut, Storrs, Connecticut, United States

Disclosure(s):

Liya Anto, PhD: No relevant financial relationship(s) with ineligible companies to disclose.

Chelsea M. Garcia, BS: No relevant financial relationship(s) with ineligible companies to disclose.

Objectives: Dietary modification to manage blood lipids is recommended as the primary preventive strategy for atherosclerosis. Polar lipids from milk (phospholipids and sphingolipids) have hypolipidemic effects and dose-dependently reduce intestinal cholesterol absorption in rodent models. The objective of the current study was to evaluate the effect of supplementation of milk polar lipids (MPL) added to milk fat on serum lipids, gut microbiome, and lipid metabolites in healthy adults.

Methods: Nineteen healthy adults (age: 28.7±5.8, BMI: 22.1±5.6) consumed either 5.3 g/day of MPL-rich powder containing 20 g/day milk fat or a nutritionally matched milk fat-containing control powder (0.3 g MPL/day) for 4 weeks, separated by a 3-week washout period in a randomized, single-blinded crossover study. The primary outcome of the study was serum total cholesterol. Secondary outcomes were other serum lipids, anthropometric measurements, gut microbiome, and fecal and plasma metabolites.

Results: Consumption of additional 5 g/day of MPL did not alter serum lipid concentrations when compared to the control. However, the additional MPL attenuated the increase in waist circumference participants experienced when consuming control powder. MPL consumption increased the levels of total ceramides and very-long-chain fatty acids (VLCFAs) in stool compared to control, while an increase in plasma d39:1 ceramide was observed after supplementing with MPL when compared to the baseline. There was also an increase in fecal acyl alpha-hydroxyl fatty acid (AAHFA) 2:0/24:0, which was found to be positively correlated with the VLCFAs, after consuming the MPL powder. The MPL and control powder significantly reduced the relative abundance of gut bacteria belonging to the order Clostridiales when compared to baseline. However, no other changes in gut microbiota composition were observed with MPL or control supplementation compared to baseline.

Conclusions: MPL consumption did not influence serum lipids or gut microbiome composition in this cohort of healthy adults. However, it was shown to increase sphingolipid metabolites in the plasma and feces.

Funding Sources: This research was supported by USDA Hatch/Multi-State Grant to C. Blesso.